Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
MINTEZOL (thiabendazole) is an oral anthelmintic approved in 1967 for treating parasitic worm infections. The exact mechanism of action involves disruption of microtubule formation in parasites, leading to immobilization and expulsion. It is indicated for a range of helminthic infections including hookworm, roundworm, and threadworm.
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), brand team focus is likely on cost management and geographic market optimization rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MINTEZOL represents a mature portfolio asset with minimal job openings, indicating limited career growth and team expansion opportunities. Roles focus on maintaining market share and managing the transition to generic competition rather than launching or expanding the product.
Worked on MINTEZOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.